BioMarin Pharmaceutical Holdings Reduced by Rafferty Asset Management

Institutional investor trims stake in biotech firm by 12% in Q3

Published on Mar. 2, 2026

Got story updates? Submit your updates here. ›

Rafferty Asset Management LLC lowered its stake in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) by 12.0% in the third quarter, according to a recent 13F filing with the Securities & Exchange Commission. The firm now owns 151,015 shares of the biotechnology company's stock, valued at $8,179,000.

Why it matters

BioMarin Pharmaceutical is a leading biotech firm focused on developing therapies for rare genetic and metabolic diseases. Changes in institutional ownership can signal shifts in market sentiment and influence the stock price.

The details

Rafferty Asset Management reduced its position in BioMarin by selling 20,508 shares during the third quarter. The firm now owns about 0.08% of BioMarin's outstanding stock. Several other major institutional investors, including Dodge & Cox, Viking Global Investors, and AQR Capital Management, have significant holdings in BioMarin and made changes to their positions in the last quarter.

  • Rafferty Asset Management filed its 13F report for the third quarter of 2026.

The players

Rafferty Asset Management LLC

An institutional investment management firm that reduced its stake in BioMarin Pharmaceutical in the third quarter of 2026.

BioMarin Pharmaceutical Inc.

A biopharmaceutical company specializing in the development and commercialization of therapies for rare genetic and metabolic diseases.

Got photos? Submit your photos here. ›

The takeaway

The reduction in Rafferty Asset Management's BioMarin holdings reflects broader shifts in institutional investor sentiment around the biotech company. While not a major sell-off, the move suggests some caution among investors despite BioMarin's leadership in rare disease treatments.